B
Bull
Bull · 25%OCS
$18.72
Scenario price
$7.290
-0.109 (-1.49%)At close
Loading chart…
- High
- 7.460
- Open
- 7.330
- VWAP
- 7.30
- Volume
- 293.70K
- Mkt Cap
- 543.39M
- Low
- 7.160
- Amount
- 2.15M
- EV/EBITDA, TTM
- -1.48
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
AI analysis of Oculis Holding AG (OCS)
HoldOculis Holding AG (OCS) is currently not a strong buy due to its low current price of $7.29 and a concerning RSI of 21.902, indicating oversold conditions. Although there is potential upside with an analyst price target of $39, the stock has experienced a significant year-to-date change of -63.55%, suggesting ongoing volatility and uncertainty. The recent positive FDA feedback could provide a catalyst for recovery, but the company is still facing substantial losses, with a net income of -28,852,000 CHF in Q1 2026. Therefore, while there are potential opportunities, the risks are substantial, and it may be prudent to hold rather than buy at this time.
Valuation Metrics
The current forward P/E ratio for Oculis Holding AG (OCS) is 0.00, compared to its 5-year average forward P/E of -5.77.
Alphio AI Price Scenarios for OCS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding OCS
Events Timeline
News
9.008-24NewsfilterOculis Initiates PIONEER-1 Trial for Privosegtor in Optic Neuritis
8.508-10GlobenewswireOculis Acquires Privosegtor to Enhance Strategic Flexibility
8.508-10GlobenewswireOculis Enters Asset Purchase Agreement with Accure
- 8.508-10Newsfilter
Oculis Acquires Privosegtor to Enhance Strategic Flexibility
9.508-07NASDAQ.COMOculis Holding AG Reports Better-Than-Expected Quarterly Loss
OCS FAQ — answered by Alphio AI
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide. It operates in the Healthcare sector.
Oculis Holding AG (OCS) is currently not a strong buy due to its low current price of $7.29 and a concerning RSI of 21.902, indicating oversold conditions. Although there is potential upside with an analyst price target of $39, the stock has experienced a significant year-to-date change of -63.55%, suggesting ongoing volatility and uncertainty. The recent positive FDA feedback could provide a catalyst for recovery, but the company is still facing substantial losses, with a net income of -28,852,000 CHF in Q1 2026. Therefore, while there are potential opportunities, the risks are substantial, and it may be prudent to hold rather than buy at this time.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.